alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › brain-amyloid

brain-amyloid

5 studies tagged brain-amyloid, dated 2023-05-10 to 2025-01-14. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Clinical utility of plasma p-tau217 in identifying abnormal brain amyloid burden in an Asian cohort with high prevalence of concomitant cerebrovascular disease 2025-01-14
  2. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease 2024-06-28
  3. Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid 2024-03-16

Studies

5 studies carry this tag.

Date range

2023 to 2025

Top journals

  • Alzheimer's & dementia : the journal of the Alzheimer's Association 3
  • Communications medicine 1
  • npj aging 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Clinical utility of plasma p-tau217 in identifying abnormal brain amyloid burden in an Asian cohort with high prevalence of concomitant cerebrovascular disease

    ✓ Peer-reviewed alzhub usefulness score 66 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025-01-14 Biomarkers

    Risk stratification for PET Aβ+ based on a plasma p-tau217 assay demonstrated potential diagnostic and prognostic utility in an Asian cohort with concomitant CeVD.

  2. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2024-06-28 Biomarkers

    Models integrating pTau217R outperformed Aβ42/Aβ40 alone, predicting amyloid levels up to 89.1 CL.

  3. Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2024-03-16 Biomarkers

    The PrecivityAD2 blood test showed strong clinical validity, with excellent agreement with brain amyloidosis by PET.

  4. Elevated plasma sclerostin is associated with high brain amyloid-β load in cognitively normal older adults

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. npj aging 2023-09-04 Biomarkers

    Osteoporosis and Alzheimer's disease (AD) mainly affect older individuals, and the possibility of an underlying link contributing to their shared epidemiological features has rarely been investigated.

  5. Integrated algorithm combining plasma biomarkers and cognitive assessments accurately predicts brain β-amyloid pathology

    ✓ Peer-reviewed alzhub usefulness score 60 out of 100. Communications medicine 2023-05-10 Biomarkers

    The innovative integrated models provide opportunity to assess Aβ pathology in a non-invasive and cost-effective way, which might facilitate AD-drug development, early screening, clinical diagnosis and prognosis evaluation.

All topic tags with their study counts